15 patents
Utility
Methods and Compounds Useful In the Sythesis of an AAK1 Inhibitor
9 Nov 23
Methods for the synthesis of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof are disclosed, as well as compounds useful therein.
Tao CHEN, Wenxue WU, Jun YAN, Xianglu ZENG, Matthew Mangzhu ZHAO
Filed: 24 Feb 23
Utility
Solid Forms of (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE and Salts Thereof
9 Nov 23
Salts of the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and solid forms thereof are disclosed, as are pharmaceutical formulations comprising them and methods of their preparation.
Qun LI, Wenxue WU, Matthew Mangzhu ZHAO
Filed: 24 Feb 23
Utility
Compounds and Methods for Treating Spasticity
19 Oct 23
Suma GOPINATHAN, Praveen TYLE, Qi Melissa YANG
Filed: 12 Apr 23
Utility
Compositions Comprising and Methods of Using Inhibitors of Sodium-glucose Cotransporters 1 and 2
13 Jul 23
Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.
Jinling CHEN, Nasser N NYAMWEYA, Kenneth K. H. ONG
Filed: 10 Jan 23
Utility
Compounds and Methods for Treating or Preventing Cardiovascular Diseases and Conditions
24 Nov 22
This invention relates to methods of treating and/or preventing cardiovascular diseases and conditions and to methods of reducing the risk of cardiovascular death, reducing the risk of hospitalization for heart failure, reducing the risk of hospitalization for heart failure, reducing the risk of urgent visits for heart failure, and slowing the progression of kidney disease.
Deepak L. BHATT
Filed: 13 Jan 22
Utility
Use of Sotagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
25 Aug 22
The invention relates to the use of sotagliflozin inpatients with type 2 diabetes mellitus and moderate renal impairment.
David BREGMAN, Ali HARIRI
Filed: 24 Jul 20
Utility
Continuous Process for Preparing the Crystalline Form II of Sotagliflozin
4 Aug 22
The present document relates to a process for the preparation of the crystalline form II of sotagliflozin from compound of formula (A), said process being continuously performed and comprising at least the steps of: a) performing in a reaction chamber the reaction of said compound of formula (A) in solution in toluene or in xylene or in mixture thereof, and preferably in toluene, and at least sodium methoxide and methanol, at a temperature below the boiling point of methanol, to form sotagliflozin in mixture with sodium salts; b) conducting in a crystallization chamber the crystallization of sotagliflozin formed in step a), in a non-aqueous solvent medium including at least toluene, or xylene or mixture thereof, and free of sodium salts, at a temperature of crystallization of the form II of sotagliflozin; and c) isolating the crystalline form II of sotagliflozin.
Bruno BUREL, Jérome CEZERAC, Stéphane DUTHEIL, Martial ETIENNE, Richard FLACHER, Antonio NOBREGA
Filed: 31 Jul 20
Utility
Process for Preparing the Crystalline Form II of Sotagliflozin
28 Jul 22
The present document relates to a process for the preparation of the crystalline form II of sotagliflozin, wherein said crystalline form II of sotagliflozin is directly obtained from the following compound of formula (A) and by using toluene or xylene or mixture thereof as solvent medium for the crystallization.
Bruno BUREL, Jérome CEZERAC, Stéphane DUTHEIL, Martial ETIENNE, Richard FLACHER, Antonio NOBREGA
Filed: 31 Jul 20
Utility
PYRAZOLO[1,5]PYRIMIDINE-BASED Compounds and Methods of Their Use to Treat Viral Infections
31 Mar 22
Suma GOPINATHAN, Praveen TYLE, Qi Melissa YANG
Filed: 19 Apr 21
Utility
Use of Sotagliflozin for the Treatment of Patients with Type 1 Diabetes Mellitus
24 Mar 22
The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI)≥27 kg/m2.
Phillip BANKS, Sangeeta SAWHNEY
Filed: 1 Dec 21
Utility
Compounds and Methods for Treating Viral Infections
24 Feb 22
Suma GOPINATHAN, Praveen TYLE, Qi Melissa YANG
Filed: 19 Apr 21
Utility
Use of Sotagliflozin for the Treatment of Patients with Type 1 Diabetes Mellitus
11 Feb 21
The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI)≥27 kg/m2.
Phillip BANKS, Sangeeta SAWHNEY
Filed: 28 Feb 20
Utility
Compositions Comprising and Methods of Using Inhibitors of Sodium-glucose Cotransporters 1 and 2
11 Feb 21
Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.
Jinling CHEN, Nasser N NYAMWEYA, Kenneth K. H. ONG
Filed: 17 Feb 20
Utility
Solid Dosage Forms of (S)-ethyl 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE
14 Jan 21
Solid pharmaceutical dosage forms comprising (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate (telotristat) are disclosed, as well as methods of making them and compositions useful in their manufacture.
Jinling CHEN, Matthew S. DEAVER, Richard J. HOLL, Kalyan NUGURU
Filed: 19 Nov 19
Utility
Crystalline Solid Forms of N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL)PHENYL)BUTANAMIDE and Methods of Their Synthesis
12 Aug 20
Methods of preparing, and solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide, and salts, solvates and cocrystals thereof, are disclosed.
Mark Stephen BEDNARZ, Kuangchu DAI, Jeffrey Manning ECKERT, Ngiap-Kie LIM, Lauren SIROIS, Wenxue WU, Matthew Mangzhu ZHAO
Filed: 22 Sep 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first